What is Radsource?
Radsource specializes in subspecialized musculoskeletal and neurological MRI interpretation, offering its flagship product, ProtonPACS. This advanced Picture Archiving and Communication System is designed for optimal performance in hospitals, imaging centers, and medical practices, aiming to elevate diagnostic accuracy and streamline workflow. The company serves a diverse clientele, including orthopaedic practices and specialty medical groups, by providing high-quality imaging and reporting services.
How much funding has Radsource raised?
Radsource has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Radsource
PPP
Public-Private Partnership
What's next for Radsource?
The substantial late-stage funding indicates Radsource is poised for significant scaling and market expansion. This capital infusion is likely to fuel further development of its ProtonPACS platform, enhance its teleradiology service offerings, and potentially broaden its reach into new medical specialties or geographic regions. The strategic nature of the recent investment suggests a focus on strengthening its competitive advantage and solidifying its leadership in the clinical imaging interpretation sector.
See full Radsource company page
